Related Experiment Videos
Evaluation of toxicity of beta-tethymustine, a new anticancer compound, in mice
M Ghosh1, U Sadhu, S Bhattacharya
1Department of Anticancer Drug Development & Chemotherapy, Chittaranjan National Cancer Institute, Calcutta, India.
Abstract:
The toxicity of beta-tethymustine, a potential anticancer compound 1 ((Cancer Lett., 119 (1997) 7-12) was assessed in normal as well as in Ehrlich ascites carcinoma (EAC), Sarcoma-180 (S-180) and Dalton' s Lymphoma (DL) tumour-bearing Swiss male mice by measuring drug-induced changes in haematological parameters, femoral bone marrow cellularity and splenic cellularity on days 9, 15 and 21 following drug treatment at the optimum dose of 8.0 mg/kg body weight from days 1 to 7. Detailed studies were also made by noting sequential changes in the above parameters in normal and EAC-bearing mice on days 12 and 18, respectively. The results indicate that the compound did not adversely affect haematopoiesis as it was observed that no significant decrease in haematological parameters and femoral marrow cellularity occurred in treated groups. Initial hyposplenic activity was, however, noted in EAC and normal treated groups on day 9 which soon reached normal count within 7-10 days after termination of drug therapy. Drug-induced hepatotoxicity and nephrotoxicity were also sequentially evaluated in normal and tumour-bearing mice on days 9, 15 and 21 but no such toxicities were detected. Also, body weight, skin and hair texture, and behavioural pattern (food and water intake and activity) did not reflect any toxic reaction in host mice at this optimum dose.
Insights
Beta-tethymustine, a potential anticancer drug, showed no significant toxicity in mice. Hematopoiesis, organ function, and overall health remained unaffected at the optimal dose, indicating its safety for further study.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Beta-tethymustine is a novel compound with potential anticancer properties.
- Assessing the toxicity of new anticancer agents is crucial for drug development.
Purpose of the Study:
- To evaluate the toxicity of beta-tethymustine in normal and tumor-bearing mice.
- To determine the effects of beta-tethymustine on hematological parameters, bone marrow, and spleen.
- To assess potential hepatotoxicity and nephrotoxicity of the compound.
Main Methods:
- Toxicity assessment in normal and tumor-bearing mice (Ehrlich ascites carcinoma, Sarcoma-180, Dalton's Lymphoma).
- Measurement of hematological parameters, femoral bone marrow cellularity, and splenic cellularity.
- Sequential evaluation of hepatotoxicity and nephrotoxicity.
- Monitoring of body weight, skin/hair texture, and behavioral patterns.
Main Results:
- Beta-tethymustine did not adversely affect hematopoiesis or femoral bone marrow cellularity.
- Transient hyposplenic activity was observed initially in some groups but normalized within 7-10 days post-treatment.
- No significant drug-induced hepatotoxicity or nephrotoxicity was detected.
- Optimal dose did not cause adverse effects on body weight, skin, hair, or behavior.
Conclusions:
- Beta-tethymustine demonstrates a favorable safety profile at the optimal dose.
- The compound does not induce significant toxicity in normal or tumor-bearing mice.
- These findings support further investigation of beta-tethymustine as a potential anticancer therapeutic.